MRKR – Marker Therapeutics Inc
Float Short %
2.41
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.1
EPS Last/This Y
0.26
EPS This/Next Y
0.14
Price
2.07
Target Price
7.87
Analyst Recom
1
Performance Q
96.15
Relative Volume
2.49
Beta
1.41
Ticker: MRKR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | MRKR | 1.44 | N/A | N/A | 0 |
| 2025-12-29 | MRKR | 1.53 | N/A | N/A | 0 |
| 2025-12-30 | MRKR | 1.48 | N/A | N/A | 0 |
| 2025-12-31 | MRKR | 1.48 | N/A | N/A | 0 |
| 2026-01-02 | MRKR | 1.54 | N/A | N/A | 0 |
| 2026-01-05 | MRKR | 1.78 | N/A | N/A | 0 |
| 2026-01-06 | MRKR | 1.86 | N/A | N/A | 0 |
| 2026-01-07 | MRKR | 2.187 | N/A | N/A | 0 |
| 2026-01-08 | MRKR | 2.07 | N/A | N/A | 0 |
| 2026-01-09 | MRKR | 2 | N/A | N/A | 0 |
| 2026-01-12 | MRKR | 1.83 | N/A | N/A | 0 |
| 2026-01-13 | MRKR | 1.73 | N/A | N/A | 0 |
| 2026-01-14 | MRKR | 1.83 | N/A | N/A | 0 |
| 2026-01-15 | MRKR | 1.75 | N/A | N/A | 0 |
| 2026-01-16 | MRKR | 1.81 | N/A | N/A | 0 |
| 2026-01-20 | MRKR | 2.15 | N/A | N/A | 0 |
| 2026-01-21 | MRKR | 2.19 | N/A | N/A | 0 |
| 2026-01-22 | MRKR | 2.05 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | MRKR | 1.43 | 54.8 | - | -0.94 |
| 2025-12-29 | MRKR | 1.53 | 54.8 | - | -0.94 |
| 2025-12-30 | MRKR | 1.47 | 54.8 | - | -0.94 |
| 2025-12-31 | MRKR | 1.46 | 54.8 | - | -0.94 |
| 2026-01-02 | MRKR | 1.54 | 54.8 | - | -0.94 |
| 2026-01-05 | MRKR | 1.76 | 54.8 | - | -0.94 |
| 2026-01-06 | MRKR | 1.86 | 54.8 | - | -0.94 |
| 2026-01-07 | MRKR | 2.18 | 54.8 | - | -0.94 |
| 2026-01-08 | MRKR | 2.08 | 54.8 | - | -0.94 |
| 2026-01-09 | MRKR | 2.01 | 54.8 | - | -0.94 |
| 2026-01-12 | MRKR | 1.83 | 54.8 | - | -0.94 |
| 2026-01-13 | MRKR | 1.72 | 54.8 | - | -0.94 |
| 2026-01-14 | MRKR | 1.83 | 54.8 | - | -0.94 |
| 2026-01-15 | MRKR | 1.75 | 54.8 | - | -0.94 |
| 2026-01-16 | MRKR | 1.81 | 54.8 | - | -0.94 |
| 2026-01-20 | MRKR | 2.14 | 54.8 | - | -0.94 |
| 2026-01-21 | MRKR | 2.18 | 54.8 | - | -0.94 |
| 2026-01-22 | MRKR | 2.07 | 54.8 | - | -0.94 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | MRKR | 0.00 | 0.40 | 2.48 |
| 2025-12-29 | MRKR | 0.00 | 0.40 | 2.48 |
| 2025-12-30 | MRKR | 0.00 | 0.40 | 2.48 |
| 2025-12-31 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-02 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-05 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-06 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-07 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-08 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-09 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-12 | MRKR | 0.00 | 0.40 | 2.48 |
| 2026-01-13 | MRKR | 0.00 | 0.40 | 2.41 |
| 2026-01-14 | MRKR | 0.00 | 0.40 | 2.41 |
| 2026-01-15 | MRKR | 0.00 | 0.40 | 2.41 |
| 2026-01-16 | MRKR | 0.00 | 0.40 | 2.41 |
| 2026-01-20 | MRKR | 0.00 | 0.40 | 2.41 |
| 2026-01-21 | MRKR | 0.00 | 0.40 | 2.41 |
| 2026-01-22 | MRKR | 0.00 | 0.40 | 2.41 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.12
Avg. EPS Est. Current Quarter
-0.19
Avg. EPS Est. Next Quarter
-0.22
Insider Transactions
Institutional Transactions
0.4
Beta
1.41
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
20
Growth Score
21
Sentiment Score
95
Actual DrawDown %
94.5
Max Drawdown 5-Year %
-98
Target Price
7.87
P/E
Forward P/E
PEG
P/S
7.25
P/B
1.85
P/Free Cash Flow
EPS
-1.23
Average EPS Est. Cur. Y
-0.94
EPS Next Y. (Est.)
-0.79
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-304.54
Relative Volume
2.49
Return on Equity vs Sector %
-105
Return on Equity vs Industry %
-89.1
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Marker Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 5
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
stock quote shares MRKR – Marker Therapeutics Inc Stock Price stock today
news today MRKR – Marker Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MRKR – Marker Therapeutics Inc yahoo finance google finance
stock history MRKR – Marker Therapeutics Inc invest stock market
stock prices MRKR premarket after hours
ticker MRKR fair value insiders trading